Table 1.
Correlation of GalNAc-T13 expression with the clinical features of the patients.
| Patients | Low GalNAc-T13 1 | High GalNAc-T13 | ||
|---|---|---|---|---|
| n | n (%) | n (%) | p 2 | |
| Total | 338 | 190 (56.2) | 148 (43.8) | |
| Mean age 51.3 (range: 27–83) | ||||
| Histological type | NS 3 | |||
| Invasive ductal carcinoma | 322 | 178 (55.3) | 144 (44.7) | |
| Others | 16 | 12 (75) | 4 (25) | |
| Histological Grade | NS | |||
| 1 | 17 | 12 (70.6) | 5 (29.4) | |
| 2 | 211 | 105 (49.8) | 106 (50.2) | |
| 3 | 51 | 31 (60.8) | 20 (39.2) | |
| T | NS | |||
| T1 | 46 | 32 (69.6) | 14 (30.4) | |
| T2 | 226 | 125 (55.3) | 101 (44.7) | |
| T3 | 43 | 19 (44.2) | 24 (55.8) | |
| T4 | 20 | 11 (55) | 9 (45) | |
| N | NS | |||
| N0 | 153 | 86 (56.2) | 67 (43.8) | |
| N+ | 182 | 101 (55.5) | 81 (44.5) | |
| Hormonal Receptors | ||||
| ER 4 (-) | 139 | 75 (54) | 64 (46) | NS |
| (+) | 189 | 112 (59.3) | 77 (40.7) | |
| PR 5 (-) | 182 | 97 (53.3) | 85 (46.7) | NS |
| (+) | 144 | 89 (61.8) | 55 (38.2) | |
| Her2 (-) | 230 | 142 (61.7) | 88 (38.3) | 0.002 |
| (+) | 87 | 37 (42.5) | 50 (57.5) | |
| Molecular types | 0.022 | |||
| Luminal A | 106 | 64 (60.4) | 42 (39.6) | |
| Luminal B | 92 | 55 (59.8) | 37 (40.2) | |
| Her2 | 41 | 14 (34) | 27 (66) | |
| TNBC 6 | 78 | 46 (59) | 32 (41) | |
| Stage | NS | |||
| I | 25 | 15 (60) | 10 (40) | |
| II | 209 | 121 (57.9) | 88 (42.1) | |
| III | 101 | 51 (50.5) | 50 (49.5)17 |
1 Cutoff established at median score (40). 2 Fisher’s exact test: p < 0.05 was considered significant. 3 Not significant. 4 Estrogen Receptor. 5 Progesterone Receptor. 6 Triple Negative Breast Cancer.